ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in adults

Last updated: March 7, 2022
Sponsor: Lyra Therapeutics, Inc.
Overall Status: Active - Recruiting

Phase

3

Condition

Sinusitis

Treatment

N/A

Clinical Study ID

TX291467
LYR-210-2021-004
  • Ages 18-100
  • All Genders

Study Summary

Evaluates the safety and efficacy of the LYR-210 matrix in patients with chronic rhinosinusitis without nasal polyps

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Symptoms of chronic rhinosinusitis for 12 weeks or more

Exclusion

Exclusion Criteria:

  • Inability to tolerate topical anesthesia of endoscopic procedure

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Bilateral LYR-210 in treatment participants vs sham procedure in patients with chronic rhinosinusitis without nasal polyps

Connect with a study center

  • Piedmont Ear, Nose, and Throat Associates

    Winston-Salem, North Carolina 27103
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.